Bioventus Inc. (NYSE:BVS) CFO Sells $29,865.99 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,541 shares of the stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $5.39, for a total value of $29,865.99. Following the completion of the sale, the chief financial officer now directly owns 25,665 shares of the company’s stock, valued at $138,334.35. The sale was disclosed in a filing with the SEC, which is available at this link.

Bioventus Stock Performance

Shares of NYSE BVS opened at $5.16 on Thursday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.01 and a current ratio of 1.53. The firm has a market cap of $408.52 million, a price-to-earnings ratio of -2.05 and a beta of 0.48. The business’s 50-day simple moving average is $4.85 and its 200-day simple moving average is $4.28. Bioventus Inc. has a 52 week low of $0.80 and a 52 week high of $6.08.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BVS. Canaccord Genuity Group raised Bioventus from a “hold” rating to a “buy” rating and increased their price objective for the stock from $3.66 to $7.00 in a research note on Thursday, December 7th. Canaccord Genuity Group raised Bioventus from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Thursday, December 7th. Finally, Craig Hallum raised their price target on Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BVS. Juniper Investment Company LLC grew its holdings in shares of Bioventus by 2.7% during the 3rd quarter. Juniper Investment Company LLC now owns 6,833,857 shares of the company’s stock worth $22,552,000 after purchasing an additional 176,870 shares in the last quarter. BlackRock Inc. lifted its position in shares of Bioventus by 7.6% during the 3rd quarter. BlackRock Inc. now owns 2,151,320 shares of the company’s stock worth $15,059,000 after buying an additional 151,471 shares during the period. Vanguard Group Inc. lifted its position in shares of Bioventus by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 1,218,500 shares of the company’s stock worth $6,421,000 after buying an additional 17,420 shares during the period. Kent Lake Capital LLC lifted its position in shares of Bioventus by 15.0% during the 3rd quarter. Kent Lake Capital LLC now owns 1,035,168 shares of the company’s stock worth $3,416,000 after buying an additional 135,168 shares during the period. Finally, First Light Asset Management LLC bought a new position in shares of Bioventus during the 1st quarter worth approximately $12,712,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.